Loading...
Publication
Farmacogenética de fármacos antidislipidémicos
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 787.44 KB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Doentes com dislipidemia grave necessitam de tomar medicação antidislipidémica
para diminuir as concentrações elevadas de colesterol de forma
a reduzirem o seu elevado risco cardiovascular. Distintos tipos e/ou doses
de estatinas levam a diferentes níveis de redução dos níveis de LDL-C, mas
existe uma grande variação interpessoal na resposta, que se pensa estar
associada a variantes nos genes envolvidos na farmacodinâmica e farmacocinética
desta classe de fármacos. Este trabalho tem como objetivo determinar
a prevalência de genótipos associados a uma menor eficácia ou a
um maior risco de efeitos secundários adversos no tratamento com estatinas
na população portuguesa. Foram genotipados vários SNPs envolvidos
no metabolismo, absorção, transporte e/ou excreção dos vários tipos de
estatinas numa amostra de adultos da população portuguesa proveniente
das diferentes regiões do país. A variante SLCO1B1*5, associada com um
maior risco de desenvolver miopatia com o tratamento com sinvastatina,
tem uma frequência 2 vezes superior na nossa amostra do que o descrito
nas bases de dados populacionais. Este fato, aliado ao grande aumento de
consumo nacional de estatinas, principalmente de sinvastatina, é um fator
importante que deve ser considerado na tomada de decisão da prescrição
de antidislipidémicos.
Patients with severe dyslipidaemia need to take antidislipidemic medication to lower the high cholesterol concentrations to decrease their increased cardiovascular risk. Different types and/or dose of statins lead to different levels of LDL-C reduction, but there is a large interpersonal variation in the response, which is thought to be associated with variants in genes involved in pharmacodynamics and pharmacokinetics of this class of drugs. This work aims to determine the prevalence of genotypes associated with a lower efficacy or a higher risk of adverse side effects in the treatment with statins in the Portuguese population. Several SNPs involved in the metabolism, absorption, transport and/or excretion of the various types of statins were genotyped in a sample of adults from the Portuguese population from different regions of the country. The SLCO1B1*5 variant, associated with an increased risk of developing myopathy on simvastatin treatment, has a frequency 2 times higher in our sample than described in the population databases. This fact, coupled with the large increase in national consumption of statins, mainly simvastatin, is an important factor that should be considered in the decision-making of the prescription of antidislipidemics.
Patients with severe dyslipidaemia need to take antidislipidemic medication to lower the high cholesterol concentrations to decrease their increased cardiovascular risk. Different types and/or dose of statins lead to different levels of LDL-C reduction, but there is a large interpersonal variation in the response, which is thought to be associated with variants in genes involved in pharmacodynamics and pharmacokinetics of this class of drugs. This work aims to determine the prevalence of genotypes associated with a lower efficacy or a higher risk of adverse side effects in the treatment with statins in the Portuguese population. Several SNPs involved in the metabolism, absorption, transport and/or excretion of the various types of statins were genotyped in a sample of adults from the Portuguese population from different regions of the country. The SLCO1B1*5 variant, associated with an increased risk of developing myopathy on simvastatin treatment, has a frequency 2 times higher in our sample than described in the population databases. This fact, coupled with the large increase in national consumption of statins, mainly simvastatin, is an important factor that should be considered in the decision-making of the prescription of antidislipidemics.
Description
Keywords
Farmacogenética Fármacos Antidislipidémicos Doenças Cardiovasculares Doenças Cardio e Cérebro-vasculares Saúde Pública Portugal
Pedagogical Context
Citation
Boletim Epidemiológico Observações. 2017;6(Supl 9):19-23
Publisher
Instituto Nacional de Saúde Doutor Ricardo Jorge, IP